Clemens Wendtner, Talha Munir, and Alessandra Tedeschi look back on the year so far in CLL, reviewing developments from clinical trials as well as real-world and comparative studies before considering how data drive individual treatment decisions.

Alessandra Tedeschi, Lucrecia Yáñez and Thorsten Zenz use interactive patient case studies to illustrate the role of prior treatment experience, genetic/cytogenetic changes, comorbidities, and patient preference in guiding treatment choices in R/R CLL.

Paolo Ghia, Davide Rossi and Anna Schuh discuss diagnosis and prognosis in CLL, including a case study on the differential diagnosis of accelerated CLL and Richter’s syndrome and a debate on the clinical relevance of IGHV and TP53 as biomarkers.

Christian Buske, Ramón García-Sanz, Véronique Leblond and Alessandra Tedeschi focus on treatment for patients with relapsed and refractory Waldenström’s macroglobulinemia, and look to the future of Waldenström’s macroglobulinemia treatment.

Véronique Leblond, Meletios Dimopoulos, Ramón García-Sanz and Wojciech Jurczak outline the topic of treatment initiation for Waldenström’s macroglobulinemia, exploring treatment options, monitoring, and unmet needs.

Christian Buske, Alessandra Tedeschi and Roger Owen chart the diagnostic journey in Waldenström’s macroglobulinemia, covering topics such as diagnostic criteria, techniques for testing, differential diagnoses, staging and the impact of specific disease-associated mutations.